You are here:

Index

A

accountability and management, 62–75

    see also finance

acronyms and abbreviations list, 169–171

administered finances, 81–82

special accounts, 79

administrative tribunal decisions, 67

advertising and market research, 157

age demographic of staff, 72

agency resource statements, 161–162

annual report errata, 160

annual report list of requirements, 163–168

apheresis, 26, 33, 151

assets and asset management, 81, 83

    administered items, 82

Audit Committee, 63, 64, 149

Australian Bleeding Disorders Registry (ABDR), 40, 42, 63

    MyABDR portal, 42–43

Australian Commission on Safety and Quality in Health Care (ACSQHC), 53, 55

Australian Haemophilia Centre Directors’ Organisation (AHCDO), 48

Australian Information Commissioner, 67

Australian National Audit Office (Auditor-General, ANAO), 63, 67

Australian Public Service Commission Employee Census, 69

Australian Red Cross Blood Service (Blood Service), 18, 32–34

    annual meeting with NBA Board, 13

    NMF (Blood and Blood Products) Special Account, 78, 79

    Review of Risk Management in the Blood Sector, 41

    see also fresh blood

B

balance sheet, 81

Baxalta Australia Pty Ltd, 46

    immunoglobulins (IVIg), 22, 35, 36, 154

    plasma and recombinant products, 22, 36, 37, 152, 153, 154

Bayer Australia Limited, 23, 37, 153

best practice tools, 49

Bio-Rad Laboratories Pty Ltd, 23, 37

bleeding, 49, 57

    see also haemophilia and bleeding disorders

blood cells, see red blood cells

Blood Service, see Australian Red Cross Blood Service

BloodNet, 19, 40, 44–45, 63

BloodSafe eLearning Australia, 55

BloodSTAR, 38, 39

Board, 12–14, 146–149

budget, see finance

C

C1 esterase, 40

Change Day, 58

classification of staff, 71, 72–73

    rationalisation of levels, 74

clinical demand, see demand

clinical practice guidelines, see Patient Blood Management (PBM) Guidelines

Clinical Transfusion Practice BEA course completions, 55

clotting factors, see Factor VIIa; Factor VIII; Factor IX

Commonwealth Ombudsman, 67

communication and promotion, 50–54, 58

    see also information communication technology

competitive tendering and contracting, 84

conferences and sector events, 50–54, 56

consultants, 85

contracts, see purchasing

Corporate Plan, 14, 64

Council of Australian Governments (COAG) Health Council, 3, 41, 81

Criteria for the clinical use of intravenous immunoglobulin in Australia, 38

critical bleeding, 57

    see also haemophilia and bleeding disorders

Critical Care PPM Guidelines module, 53

CSL Behring Pty Ltd, 22, 152, 153, 154–155

    Fractionation Agreement, 27, 34–35

    imports, 35, 37, 154, 155

    red cell diagnostic reagent products, 37

Customer Service Charter, 67

D

data developments, 40–41, 57

    see also information communication technology

Deed of Agreement, Red Cross, 32–34, 41

deliverables, 18–19

demand, 18, 24–31

    platelets, 26, 41

diagnostic reagent products, 23, 37

disability reporting, 160

discards, see wastage

donor management, Blood Service, 33

E

ecologically sustainable development, 157–159

education and training, 54–55

employees, 68, 69–75, 156

enterprise agreement, 72–73

environmental performance, 157–159

exempt contracts, 84

expenditure, see finance

external scrutiny, 67

F

Factor VIIa (rFVIIa), 23, 28, 29

    supply contracts, 36, 152

Factor VIII (rFVIII), 27–28

    clinical practice guidelines, 48

    inhibitor bypass agent (FEIBA), 28, 29, 152

    supply contracts, 36, 152, 153

Factor IX (rFIX), 27, 28

    clinical practice guidelines, 48

    supply contracts, 36, 153

finance, 78–143, 161–162

    Audit Committee, 63, 64, 149

    Blood Service, 33, 34, 78

    grant programmes, 160

    see also purchasing

financial assets, 81

financial statements, 86–143

    audit report, 80

fractionation, see plasma and recombinant products

fraud control, 68

freedom of information, 160

fresh blood, 21, 24–26, 32–34

    components supplied under contract, 151

    see also Australian Red Cross Blood Service; patient blood management; platelets;
    red blood cells

frozen blood products, 34

functions and role, 2–3, 12

G

gender of staff, 71

General Manager, 3, 62, 63

    review of year, 8–11

governance, 62–64

    blood sector data and information, 41

    immunoglobulin arrangements, 38–39, 63

grant programmes, 160

Grifols Australia, 23, 35, 37

H

haematology, 30, 39

haemophilia and bleeding disorders, 40, 42, 48

    MyABDR portal, 42–43

    see also Factor VIIa; Factor VIII; Factor IX

haemovigilance, 40

health provider Charter, 66

horizon scanning, 46

human resources, 68, 69–75, 156

I

immunoglobulins (IVIg), 27, 29–31, 154–155

    CSL Behring Ltd supplies, 26, 27, 35, 154–155

    governance arrangements, 38–39, 63

imported supplies, 22–23, 30, 35–36, 154, 155

immunology, 30, 39

income, see finance

Indigenous employees, 71

information communication technology (ICT), 42–45, 62

    BloodNet, 19, 40, 44–45, 63

    BloodSafe eLearning Australia, 55

    BloodSTAR, 38, 39

    Patient Blood Management website pages, 49

Information Publication Scheme statement, 160

internal audit, 63, 64

international horizon scanning, 46

inventory management

    Blood Service, 33

    BloodNet, 19, 40, 44–45, 63

    CSL Behring Ltd, 35, 37

imported intravenous immunoglobulin, 36

imported plasma and recombinant blood products, 37

iron products, 49

J

Johnson & Johnson Medical Pty Ltd, 23, 37

judicial decisions, 67

Jurisdictional Blood Committee (JBC), 39, 40

    endorsements and approvals, 40, 41, 47, 57

    Strategic Plan, 8, 14, 64

K

key performance indicators,
see performance indicators

L

legal actions, 67

legislation, 3, 12, 68, 78

liabilities, see assets

M

management and accountability, 62–75

    see also finance

Management Committee, 62

market research and advertising, 157

Massive Transfusion Registry, 57

Medical PBM Guidelines module, 55

Medical Services Advisory Committee review, 40

Ministers, 3

MyABDR portal, 42–43

N

National Blood Account, 78, 79

National Blood Agreement, 3, 57, 78, 82

    evaluations undertaken under Schedule 4, 40

National Blood and Blood Product Wastage Reduction Strategy 2013–2017, 40, 48

National Blood Authority Act 2003, 3, 12, 78

National Blood Authority Board, 12–14, 146–149

National Blood Awards for Excellence in the Management of Blood, 54

National Blood Research and Development Strategic Priorities 2013–2016, 57

National Blood Sector Data and Information Governance Framework, 41

National Blood Sector Data and Information Strategy and Scorecard 2013–2016, 40–41

National Blood Sector Education and Training Strategy 2013– 2016, 54–55

National Blood Sector ICT Strategy 2013–16, 42

National Blood Supply Contingency Plan, 41

National Blood Symposium, 53–54

National Education and Training Committee, 55

National Haemophilia Guidelines, 48

National Haemovigilance Report 2015, 40

National Immunoglobulin Governance Advisory Committee, 39

National Inventory Management Framework, 33

National Managed Fund Action Plan Review, 41

National Managed Fund (Blood and Blood Products) Special Account, 78, 79

National Patient Blood Management Guidelines Implementation Strategy 2013–2017, 48

National Policy Access to Government Funded Immunoglobulin Products in Australia, 39

National Safety and Quality Health Service Standards, 55

National Service Requirements and Standards, 33

National Supply Plan and Budget, 21–31

National Supply List inclusions, 30, 40

Neonatal and Paediatric PPM Guidelines module, 48

neurology, 30, 39

non-English speaking backgrounds, employees from, 71

non-financial assets, 81

non-ongoing staff, 71

normal immunoglobulin (NIg), 31, 154

Novo Nordisk Pharmaceuticals Pty Ltd, 23, 36, 37, 152

O

Obstetrics and Maternity PBM Guidelines module, 19, 53, 56

occupational health and safety, 75, 156

Octapharma Australia Pty Ltd, 23, 35, 36, 154

Ombudsman, 67

ongoing staff, 71

online services, see information communication technology

operating result, 80–82

    Blood Service, 33

operational planning, 64–66

organ transplantation, 39

organisation and structure, 2–14, 62–64

organisation chart, 4

Ortho-Clinical Diagnostics, 23, 37

outcome and objectives, 18–58

Output Based Funding Model (OBFM), 24, 32

overseas horizon scanning, 46

P

Parliamentary committees, 67

patient blood management, 19, 47–49, 58

    National Blood Awards, 54

Patient Blood Management (PBM) Guidelines, 19, 47–48, 53, 56

    BloodSafe eLearning Australia releases based on, 55

    companion, 49, 53

    Module 1 review, 47, 63

payroll contract, 74

people management, 68, 69–75, 156

performance indicators, 18–19

    Australian Red Cross Blood Service, 32–33

    CSL Australian Fractionation Agreement, 34–35

    environmental performance, 158–159

    imported intravenous immunoglobulin, 36

    imported plasma-derived and recombinant products, 37

performance pay, 74

performance reporting, 18–58

Pfizer Australia Pty Ltd, 23, 36, 37, 153

planning, 8, 14, 64–66

plasma and recombinant products, 21, 22–23, 27–31

    supply contracts, 34–37, 152–155

    Supply Risk and Mitigation Project, 42

    see also immunoglobulins

plasma for fractionation, 24, 26, 27, 34–35, 151

plasmapheresis, 26, 33, 151

platelets, 26, 41, 151

    discards, 50

    shelf-life, 34

Preoperative Bleeding Risk Assessment Tool, 49

prices, 24, 26, 27, 151–155

procurement, see purchasing

productivity gains, 74

Project Governance Boards, 63

promotion and communication, 50–54, 58

    see also information communication technology

Public Governance, Performance and Accountability Act 2013, 3

Public Governance, Performance and Accountability Rule 2014, 68

Public Service Act 1999, 3

purchasing, 84–85

    advertising and market research, 157

payroll contract, 74

purchasing of blood and blood product supply, 3, 21–25, 78–79, 81–82, 151–155

    contract management, 18, 32–37

plasma and recombinant products, 21, 22–23, 27, 30, 34–37, 152–155

    savings, 8–9, 27; supply contracts, 35, 36

    see also inventory management

Q

quality improvement initiatives, see safe and efficient use

Queensland Health, 53

R

recombinant products, see plasma and
recombinant products

red blood cells, 24, 25, 49, 151

    data linkage, 41

    diagnostic reagent products, 23, 37

    discards, 50

    inventory management, 33

remuneration of staff, 72–73, 74

Report on the Issue and Use of IVIg 2013–14, 30

research and development, 57

    Blood Service, 34

resource statements, 161–162

revenue, see finance

Review of Risk Management in the Blood Sector, 41

risk management, 64

    blood sector, 41–42

    preoperative bleeding, 49

Rural Medicine Australia 2014 conference, 51–52

S

safe and efficient use, 19, 47–58

    expenditure resulting from measures introduced, 27

salary and remuneration, 72–73, 74

satisfaction with Blood Service, 33

savings, 8–9, 24–25, 27

supply contracts, 35, 36

sector monitoring, 46

security of supply, see supply

Senior Executive Management, 62, 63

senior executive service, 73, 74

Service Charter, 67

small business, procurement initiatives to support, 85

solid organ transplantation, 39

special accounts, 78–79

staff, 68, 69–75, 156

stakeholder engagement programme, 13–14

standards, 53, 55

    Blood Service, 33

    haemovigilance, 40

Statement on national stewardship expectations for the supply of blood and blood products, 10, 48

subcutaneous immunoglobulin (SCIg), 30, 31, 154

supply, 18, 21–37, 151–155

    platelet shortage, 41

    risk mitigation for plasma and recombinant products project, 42

supply chain management,
see inventory management

T

tenders, see purchasing

training, 54–55

Transfusion Outcomes Research Collaborative, 57

transfusions, 49, 55, 57, 58

tribunal decisions, 67

V

values, 70

W

wastage (discards), 40, 50

    reduction strategy, 40, 48

website services, see information communication technology

whole blood, 26, 33, 151

work health and safety, 75, 156